NCT03614260进行中（未招募）不适用
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 225
- 试验地点
- 91
- 主要终点
- Change in average daytime ambulatory systolic BP
研究概览
简要总结
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously or currently prescribed antihypertensive therapy
- •Average office BP ≥ 140/90 mmHg <180/120 mmHg while stable for at least 4 weeks on 0-2 classes of antihypertensive medication
- •Documented daytime ABP ≥ 135/85 mmHg and < 170/105 mmHg after 4-week washout/run-in period
排除标准
- •Lacks appropriate renal artery anatomy for treatment
- •Known, uncorrected causes of secondary hypertension other than sleep apnea
- •Type I diabetes mellitus or uncontrolled Type II diabetes
- •eGFR of <40
- •Brachial circumference ≥ 42 cm
- •Any history of cerebrovascular event or severe cardiovascular event, or history of stable or unstable angina within 12 months prior to consent
- •Repeat (>1) hospitalization for hypertensive crisis within 12 months prior to screening period, or any hospitalization for hypertensive crisis within 3 months prior to screening period
- •Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- •Primary pulmonary hypertension
- •Night shift workers
- •Pregnant, nursing or planning to become pregnant
结局指标
主要结局
Change in average daytime ambulatory systolic BP
时间窗: From baseline to 2 months post-procedure
Incidence of Major Adverse Events (MAE)
时间窗: From baseline to 30 days post-procedure
次要结局
- Change in average 24-hr ambulatory diastolic BP(From baseline to 2 months post-procedure)
- Change in average office systolic BP(From baseline to 2 months post-procedure)
- Change in average daytime ambulatory diastolic BP(From baseline to 2 months post-procedure)
- Change in average office diastolic BP(From baseline to 2 months post-procedure)
- Change in average 24-hr ambulatory systolic BP(From baseline to 2 months post-procedure)
- Change in average home systolic BP(From baseline to 2 months post-procedure)
- Change in average home diastolic BP(From baseline to 2 months post-procedure)
研究者
研究点 (91)
Loading locations...
相似试验
招募中
不适用
The GOAL27-6 StudyHead and Neck CancerNCT05859828East and North Hertfordshire NHS Trust60
已完成
2 期
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic LeukemiaChronic Myelomonocytic LeukemiaNCT01350947University of Utah11
撤回
2 期
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)CarcinomaAdenocarcinomaUterine Cervix Adenosquamous CarcinomaNCT01301612Eurofarma Laboratorios S.A.
已完成
1 期
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NCT02221739NYU Langone Health39
进行中（未招募）
2 期
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)Relapsed/Refractory Small Cell Lung CancerNCT05060016Amgen222